title: Treatment of metastatic renal cell carcinoma.
abstract: The median survival of patients with metastatic renal cell carcinoma (mRCC) has increased from 10 months to more than 40 months since the advent of targeted therapy. Sunitinib and bevacizumab represent the first-line standards of care for patients with clear cell mRCC. Temsirolimus is the standard of care for those with poor-risk features. Additionally, exploratory analyses of the temsirolimus data indicate important benefits for those with non-clear-cell mRCC. Everolimus has proved its efficacy in second-line therapy. Sunitinib and sorafenib are also effective for non-clear-cell histological subtypes and after failure of first-line treatment. Potential survival benefits can also be derived from cytoreductive nephrectomy (CNT) in patients previously exposed to sunitinib or bevacizumab. Phase III studies are ongoing to address the importance of CNT in the targeted therapy era. Such information is crucial to ensure timely delivery of a combination of medical and surgical therapies to this patient population.
authors.affiliation: Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec H2X 3J4, Canada.
authors.forename: Maxine
authors.initials: M
authors.lastname: Sun
authors.forename: Giovanni
authors.initials: G
authors.lastname: Lughezzani
authors.forename: Paul
authors.initials: P
authors.lastname: Perrotte
authors.forename: Pierre I
authors.initials: PI
authors.lastname: Karakiewicz
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy*; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007376:Interleukin-2; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000068258:Bevacizumab; C401859:temsirolimus; D007372:Interferons; D000077157:Sorafenib; D020123:Sirolimus
references.citation: J Urol. 2007 Nov;178(5):1883-7
references.pmid: 17868732
references.citation: Urology. 2009 Oct;74(4):837-41
references.pmid: 19616828
references.citation: J Clin Oncol. 2002 Jan 1;20(1):289-96
references.pmid: 11773181
references.citation: J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63
references.pmid: 18840822
references.citation: Eur Urol. 2008 Dec;54(6):1373-8
references.pmid: 18692304
references.citation: Eur J Cancer. 1991;27 Suppl 4:S84-7
references.pmid: 1724728
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4469-74
references.pmid: 19652053
references.citation: Cancer. 2007 Dec 1;110(11):2468-77
references.pmid: 17932908
references.citation: Eur Urol. 2009 Dec;56(6):959-71
references.pmid: 19748725
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references.pmid: 20100962
references.citation: J Urol. 2004 Mar;171(3):1071-6
references.pmid: 14767273
references.citation: Lancet. 2007 Dec 22;370(9605):2103-11
references.pmid: 18156031
references.citation: J Support Oncol. 2006 Apr;4(4):191-9
references.pmid: 16669463
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4536-41
references.pmid: 17876014
references.citation: J Immunother. 2009 Feb-Mar;32(2):181-5
references.pmid: 19238017
references.citation: J Clin Oncol. 2008 Aug 1;26(22):3743-8
references.pmid: 18669461
references.citation: Med Oncol. 2010 Jun;27(2):373-8
references.pmid: 19399651
references.citation: Lancet Oncol. 2009 Aug;10(8):757-63
references.pmid: 19615940
references.citation: Cancer Res. 1990 Jul 15;50(14):4190-4
references.pmid: 2364374
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1432-9
references.pmid: 19224847
references.citation: Can Urol Assoc J. 2008 Jun;2(3):175-82
references.pmid: 18682778
references.citation: Urology. 1995 May;45(5):758-62
references.pmid: 7747370
references.citation: Cancer. 2009 Jan 1;115(1):61-7
references.pmid: 19051290
references.citation: J Urol. 1997 Nov;158(5):1691-5
references.pmid: 9334580
references.citation: J Clin Oncol. 1995 Mar;13(3):688-96
references.pmid: 7884429
references.citation: N Engl J Med. 2007 Jan 11;356(2):185-7
references.pmid: 17215538
references.citation: J Clin Oncol. 1999 Sep;17(9):2859-67
references.pmid: 10561363
references.citation: J Surg Res. 2001 Apr;96(2):173-82
references.pmid: 11266270
references.citation: Urology. 2003 Oct;62(4):636-40
references.pmid: 14550433
references.citation: J Clin Oncol. 1999 Aug;17(8):2530-40
references.pmid: 10561319
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7889-96
references.pmid: 16204015
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4462-8
references.pmid: 19652060
references.citation: J Clin Oncol. 2008 Jan 1;26(1):127-31
references.pmid: 18165647
references.citation: J Urol. 2008 Jan;179(1):81-6; discussion 86
references.pmid: 17997441
references.citation: J Urol. 2009 Jul;182(1):29-34; discussion 34
references.pmid: 19447417
references.citation: Cancer. 2009 May 15;115(10 Suppl):2361-7
references.pmid: 19402059
references.citation: J Clin Oncol. 2002 May 1;20(9):2376-81
references.pmid: 11981011
references.citation: J Exp Med. 1979 Jun 1;149(6):1460-76
references.pmid: 156241
references.citation: Semin Oncol. 2009 Dec;36 Suppl 3:S26-36
references.pmid: 19963097
references.citation: Cancer J Sci Am. 2000 Feb;6 Suppl 1:S88-92
references.pmid: 10685666
references.citation: J Clin Oncol. 2010 Jan 10;28(2):207-14
references.pmid: 19949018
references.citation: Nat Rev Urol. 2009 Jul;6(7):375-83
references.pmid: 19528960
references.citation: BJU Int. 2008 Sep;102(6):692-6
references.pmid: 18410444
references.citation: Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7
references.pmid: 9457402
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1280-9
references.pmid: 19171708
references.citation: Value Health. 2007 Jul-Aug;10(4):285-93
references.pmid: 17645683
references.citation: Adv Immunol. 1991;50:147-235
references.pmid: 1950796
references.citation: Urology. 2009 Feb;73(2):342-6
references.pmid: 19041122
references.citation: J Urol. 1990 Sep;144(3):614-7; discussion 617-8
references.pmid: 2201792
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5788-93
references.pmid: 19884559
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4076-81
references.pmid: 19636008
references.citation: Ann Surg Oncol. 2004 Jan;11(1):71-7
references.pmid: 14699037
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2431-6
references.pmid: 18413834
references.citation: Lancet. 2001 Sep 22;358(9286):966-70
references.pmid: 11583750
references.citation: N Engl J Med. 2003 Jul 31;349(5):427-34
references.pmid: 12890841
references.citation: Cancer. 2009 May 15;115(10 Suppl):2355-60
references.pmid: 19402066
references.citation: Cancer. 1995 Aug 15;76(4):687-94
references.pmid: 8625167
references.citation: J Surg Res. 2002 Jun 1;105(1):43-7
references.pmid: 12069500
references.citation: World J Urol. 2005 Jul;23(3):161-5
references.pmid: 15711829
references.citation: Clin Genitourin Cancer. 2007 Dec;5(7):427-32
references.pmid: 18272024
references.citation: Future Oncol. 2009 Aug;5(6):859-69
references.pmid: 19663735
references.citation: N Engl J Med. 1987 Apr 9;316(15):889-97
references.pmid: 3493432
references.citation: Cancer. 2009 May 15;115(10 Suppl):2262-72
references.pmid: 19402056
references.citation: Lancet. 1999 Jan 2;353(9146):14-7
references.pmid: 10023944
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5422-8
references.pmid: 18936475
references.citation: Eur Urol. 2009 Jan;55(1):237-9; quiz 239
references.pmid: 18804907
references.citation: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
references.pmid: 15674877
references.citation: Drugs. 1993 Feb;45(2):177-211
references.pmid: 7681371
references.citation: JAMA. 2006 Jun 7;295(21):2516-24
references.pmid: 16757724
references.citation: J Natl Cancer Inst. 1993 Apr 21;85(8):622-32
references.pmid: 8468720
references.citation: J Clin Oncol. 1991 Apr;9(4):694-704
references.pmid: 2066765
references.citation: J Clin Oncol. 2006 Jun 1;24(16):2505-12
references.pmid: 16636341
references.citation: CA Cancer J Clin. 1993 May-Jun;43(3):177-87
references.pmid: 8490757
references.citation: J Urol. 1999 Jul;162(1):43-5
references.pmid: 10379736
references.citation: Cancer. 2006 Dec 1;107(11):2617-21
references.pmid: 17083126
references.citation: N Engl J Med. 2001 Dec 6;345(23):1655-9
references.pmid: 11759643
references.citation: Med Oncol. 2009;26(2):202-9
references.pmid: 19229667
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: Acta Oncol. 1990;29(2):155-62
references.pmid: 2185803
references.citation: J Clin Oncol. 2006 Jan 1;24(1):16-24
references.pmid: 16330672
references.citation: J Urol. 1995 Jul;154(1):32-4
references.pmid: 7776449
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: Lancet Oncol. 2007 Nov;8(11):975-84
references.pmid: 17959415
references.citation: J Urol. 2007 Mar;177(3):855-60; discussion 860-1
references.pmid: 17296358
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3127-32
references.pmid: 12915604
references.citation: Cancer. 2009 May 15;115(10 Suppl):2321-6
references.pmid: 19402067
references.citation: Urology. 2000 Jan;55(1):36-40
references.pmid: 10654891
references.citation: Science. 1976 Sep 10;193(4257):1007-8
references.pmid: 181845
references.citation: Urology. 2008 Oct;72(4):864-8
references.pmid: 18684493
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4068-75
references.pmid: 19652072
references.citation: Cancer. 2006 Nov 15;107(10):2375-83
references.pmid: 17048248
references.citation: Eur Urol. 2008 Apr;53(4):845-8
references.pmid: 18053636
references.citation: J Clin Oncol. 2005 Jan 1;23(1):133-41
references.pmid: 15625368
references.citation: Cancer. 2010 Jan 15;116(2):347-54
references.pmid: 19921736
references.citation: Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):697s-702s
references.pmid: 17255296
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3312-8
references.pmid: 19451442
references.citation: Cancer Treat Rev. 2009 Dec;35(8):733-7
references.pmid: 19699588
references.citation: J Urol. 2008 Jul;180(1):94-8
references.pmid: 18485389
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381
references.citation: Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72
references.pmid: 18774306